A detailed history of Cetera Investment Advisers transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 11,618 shares of ARWR stock, worth $220,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,618
Previous 13,982 16.91%
Holding current value
$220,277
Previous $363,000 38.29%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.36 - $29.54 $45,767 - $69,832
-2,364 Reduced 16.91%
11,618 $224,000
Q2 2024

Aug 22, 2024

BUY
$21.87 - $28.24 $35,254 - $45,522
1,612 Added 13.03%
13,982 $363,000
Q1 2024

May 24, 2024

BUY
$27.21 - $39.48 $336,587 - $488,367
12,370 New
12,370 $353,000
Q1 2022

May 13, 2022

SELL
$39.62 - $69.97 $4.74 Million - $8.37 Million
-119,565 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $174 - $247
3 Added 0.0%
119,565 $7.93 Million
Q3 2021

Nov 16, 2021

BUY
$58.38 - $84.96 $796,419 - $1.16 Million
13,642 Added 12.88%
119,562 $7.46 Million
Q2 2021

Aug 13, 2021

SELL
$62.15 - $90.32 $488,996 - $710,637
-7,868 Reduced 6.91%
105,920 $8.77 Million
Q1 2021

May 17, 2021

SELL
$61.35 - $90.47 $79,877 - $117,791
-1,302 Reduced 1.13%
113,788 $7.55 Million
Q4 2020

Feb 17, 2021

BUY
$43.82 - $85.37 $4.23 Million - $8.24 Million
96,564 Added 521.24%
115,090 $8.83 Million
Q3 2020

Nov 13, 2020

BUY
$33.21 - $51.27 $79,405 - $122,586
2,391 Added 14.82%
18,526 $798,000
Q2 2020

Aug 13, 2020

BUY
$26.12 - $43.27 $421,446 - $698,161
16,135 New
16,135 $697,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.